FDA Approves Two Hepatitis C Drugs - Sovaldi and Harvoni - for Pediatric Patients

April 7, 2017 -- The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news